Final Approval In Glumetza Antitrust Deal Gives Attys $50M
By J. Edward Moreno · February 4, 2022, 5:22 PM EST
A California federal judge granted final approval of three settlements resolving direct buyers' class claims that drugmakers plotted to delay the generic version of the blockbuster diabetes drug Glumetza, awarding $50 million...
To view the full article, register now.